Recent News

• 04.07.2026 - OKYO Pharma Announces Scientific Advisory Board Meeting and Urcosimod Data Presentation During ASCRS Annual Meeting
• 03.19.2026 - OKYO Pharma Announces Director Acquires Shares
• 03.19.2026 - OKYO Pharma Announces Chief Development Officer and Director Acquires Shares
• 03.18.2026 - OKYO Pharma Reports New Phase 2 Data Demonstrating Meaningful Improvements in Patient-Reported Quality of Life Outcomes with Urcosimod in Neuropathic Corneal Pain
• 02.13.2026 - OKYO Pharma Announces Pricing of $20 Million Public Offering of Ordinary Shares

Recent Filings

• 03.19.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 03.19.2026 - EX-99.1 EX-99.1
• 03.19.2026 - EX-99.1 EX-99.1
• 03.19.2026 - EX-99.1 EX-99.1
• 03.19.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 03.19.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 03.18.2026 - 3 Initial statement of beneficial ownership of securities
• 03.18.2026 - 3 Initial statement of beneficial ownership of securities
• 03.18.2026 - EX-99.1 EX-99.1
• 03.18.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]